• Active, not recruiting

NCT03302403: Phase 1 - Clinical Study of Redirected Autologous T Cells With a CAR

Updated: Apr 25

NCT03302403: Phase 1 - Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors


cart

A single arm, open-label pilot study is designed to determine the safety, efficacy and cytokinetics of CAR T cells in patients with malignant tumors with positive antigen targets. CAR T cells are genetically engineered to express single-chain variable fragment (scFv) targeting indication-specific antigens.

The investigational CAR T cells and proposed indications are as follows: CAR-CD19 T cells for B cell leukaemia/lymphoma; CAR-BCMA T cells for myeloma; CAR-GPC3 T cell for hepatocellular carcinoma; CAR-CLD18 T cells for pancreatic carcinoma and adenocarcinoma of esophagogastric junction.


Sponsor: Kang YU

Collaborator: CARsgen Therapeutics Co., Ltd.



ClinicalTrials.gov Identifier: NCT03302403


Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors


Click here for details on Clinicaltrials.gov

 

CART - BCMA : National Cancer Institute


Genetic: CAR-CD19 T cell

Genetic: CAR-BCMA T cell

Genetic: CAR-GPC3 T cell

Genetic: CAR-CLD18 T cell

Drug: Fludarabine

Drug: Cyclophosphamide

 

703.Adoptive Immunotherapy: Mechanisms and New Approaches| November 13, 2019

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

https://doi.org/10.1182/blood-2019-126104


China, Zhejiang

First Affiliated Hospital of Wenzhou Medical University Wenzhou,

Zhejiang, China, 325000







Posts Archive